Sat, 24 Jun 2023 | BUSINESS SALE
Abcam, which provides innovative products and solutions for the life science industry, yesterday announced that it was going to initiate a process to explore strategic alternatives for the company.
Meanwhile, some shareholders are suggesting this is a ploy to derail a proxy bid.
The company statement read, “The comprehensive process will begin immediately and will evaluate a broad range of options to maximise shareholder value, including a potential sale of the Company. “
The company said that it had received strategic enquiries from multiple parties over the past few weeks.
“Our Board is fully aligned in its belief that the best way to maximise value for shareholders is to comprehensively review the Company’s strategic alternatives, including a potential sale of Abcam. We will pursue the pathway that maximises value for our shareholders and also ensures successful outcomes for our customers and employees.”
The board of directors has retained Lazard and Morgan Stanley as financial advisers to assist in the review of strategic alternatives.
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays, and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and e-commerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam’s worldwide customer base of approximately 750,000 life science researchers’ uses Abcam’s antibodies, reagents, biomarkers, and assays. The company recorded revenue in the 2022 fiscal year of £362 million and its current market capitalisation is over £3 billion.
Founder, shareholder and ex-CEO Jonathan Milner has been outspoken in his view that the company is undervalued, and has proposed that he return to duty as executive Chairman. Milner suggested in a letter to shareholders that the notion of suitors lining up is merely one of many “tactics the entrenched Abcam board and management team have employed since my recent efforts to restore financial and operational performance and maximise value for all shareholders”.
He went on to say: “The company’s claims about ‘strategic enquiries’ are a blatant and desperate attempt to derail a proxy challenge. If you want the company to provide return on your investment through a strategic transaction, you should vote FOR the proposals, not against them.”
Over the past 10 years, our clients have built a solid and profitable business with a well-respected reputation helping clients in the higher education sector improve service delivery through a better understanding of students’ lives, before, during,...
The business has developed a highly specialised platform that acquires remotely sensed geospatial data from various sources, including satellites, and uses AI-powered analytics to provide customers with actionable insights.
Established and highly regarded Ltd Co with impressive national/international reputation and client base. The company offers a one stop design-to-commissioning service of state-of-the-art fire, intruder alarm, and CCTV systems.
31
|
Jan
|
Boda Group takes 40 per cent stake in customer experience group | BUSINESS NEWS
Digital marketing agency collective The Boda Group has taken...
31
|
Jan
|
Cargo bike firm Zedify crashes into administration | ADMINISTRATION
Zedify, the UK's largest electric cargo bike delivery n...
31
|
Jan
|
Phoenix Gas set to keep rising after sale to private investment firm GIL | BUSINESS SALE
Stoke-on-Trent-based Phoenix Gas has been sold to private in...
Business Sale Report is the complete resource for finding genuine acquisition opportunities.
Join today to receive:
All this and much more, including the latest M&A news and exclusive resources
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.